A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00563355

Enrollment

Registered

2007-11-26

Start date

2001-02-28

Completion date

2003-11-30

Last updated

2011-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Chronic Disease, Kidney Diseases

Keywords

chronic kidney disease, cardiovascular disease

Brief summary

The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease

Interventions

DRUGerythropoietin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 75 Years

Inclusion criteria

* Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb * Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months * Patients below the age of 75

Exclusion criteria

* Patients with valvular heart disease/congenital heart disease * Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery * Patients with history of heart failure * Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months * Patients with thalassemic trait or haemoglobinopathies * Patients with underlying haematological malignancies * Patients with active bleeding * Patients with uncorrected iron or other vitamins deficiencies * Patients with poor general condition

Design outcomes

Primary

Measure	Time frame
endothelial function and atherosclerosis	6 month, 1 year
cardiac hypertrophy and cardiac function	6 month, 1 year

Secondary

Measure	Time frame
nutrition status	6 month, 1 year
residual renal function	6 month, 1 year
quality of life	6 month, 1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026